5/14/2014 7:07:26 AM
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months ended March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by